Scientific Programmes

Experimental Therapeutics Programme

CNIO - Lilly Epigenetics Section

Head of Section:  María José Barrero
Overview

Eli Lilly and CNIO are collaborating on the identification and validation of novel targets in cancer epigenetics. Our Section is funded through a research contract with Eli Lilly and focuses on the identification of small molecular weight molecules that are able to modulate the epigenome of malignant cells, and ultimately block the growth and spread of tumours. Potential targets (FIGURE) are being validated in vitro and in vivo using animal models developed at the CNIO. Furthermore, we are currently setting up biochemical and cell-based assays with the aim of understanding the mechanism of action of such targets at the molecular level.